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Abstract 
Background: Hepcidin secreted by hepatocytes is a key regulator of iron metabolism 
throughout the body. Hepcidin concentrations are increased in chronic kidney disease 
(CKD), contributing to abnormalities in iron metabolism. Levels of indoxyl sulfate (IS), 
a uremic toxin, are also elevated in CKD. However, the effect of IS accumulation on 
iron metabolism remains unclear.  
Methods: We used HepG2 cells to determine the mechanism by which IS regulates 
hepcidin concentrations. We also used a mouse model of adenine-induced CKD. The 
CKD mice were divided into two groups: one was treated using AST-120 and the other 
received no treatment. We examined control mice, CKD mice, CKD mice treated using 
AST-120, and mice treated with IS via drinking water. 
Results: In the in vitro experiments using HepG2 cells, IS increased hepcidin 
expression in a dose-dependent manner. Silencing of the aryl hydrocarbon receptor 
(AhR) inhibited IS-induced hepcidin expression. Furthermore, IS induced oxidative 
stress, and antioxidant drugs diminished IS-induced hepcidin expression. 
Adenine-induced CKD mice demonstrated an increase in hepcidin concentrations; this 
increase was reduced by AST-120, an oral adsorbent of the uremic toxin. CKD mice 
showed renal anemia, decreased plasma iron concentration, increased plasma ferritin, 
and increased iron content in the spleen. Ferroportin was decreased in the duodenum 
and increased in the spleen. These changes were ameliorated by AST-120 treatment. 
Mice treated by direct IS administration showed hepatic hepcidin upregulation. 
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Conclusion: IS affects iron metabolism in CKD by participating in hepcidin regulation 
via pathways that depend on AhR and oxidative stress.  
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Short summary 
In contrast with absolute iron deficiency, functional iron deficiency is common, and it 
causes renal anemia in chronic kidney disease. In the present study, we found that 
indoxyl sulfate (IS)—a uremic toxin—contributes to renal anemia by regulating 
hepcidin concentrations and thus impairing iron absorption and causing ectopic iron 
accumulation. This study presents the first findings regarding the effect of IS on 
hepcidin concentrations and thus on whole-body iron metabolism in CKD. 
 
 
Introduction 
 As the incidence of chronic kidney disease (CKD) has increased worldwide, 
morbidity and mortality in the general population have worsened [1, 2]. Patients with 
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CKD often have renal anemia, and they are generally treated using both iron 
supplementation and an erythropoiesis-stimulating agent (ESA). However, in 
individuals with CKD, iron treatment may lead to over supplementation due to 
functional iron deficiency. 
 Hepcidin is a secreted protein mainly derived from the liver that plays a crucial 
role in the regulation of iron metabolism [3]. Specifically, hepcidin regulates iron 
efflux from intracellular iron by inducing the internalization and degradation of 
ferroportin (FPN), a cellular iron exporter [4]. Hepcidin levels are increased in patients 
with CKD [5], as well as in experimental animal models of CKD [6, 7]. Increased 
hepcidin levels in patients with CKD may impair the proper use of stored iron and lead 
to FPN degradation, thereby contributing to functional iron deficiency and 
dysregulation of iron metabolism. 
 Indoxyl sulfate (IS) is a protein-bound uremic toxin and a metabolite of indole, a 
tryptophan metabolite that is synthesized by intestinal bacteria. In healthy subjects, IS 
is excreted in the urine via the renal proximal tubule; however, patients with impaired 
renal function show reduced excretion of IS, and it accumulates in their blood [8]. The 
accumulation of IS further predicts renal dysfunction in CKD [9], and high serum IS 
levels are associated with cardiovascular diseases and mortality in CKD patients [10]. 
IS also induces reactive oxygen species (ROS) as well as inflammation, and exerts 
adverse effects on various organs [11]. AST-120, a sorbent of uremic toxin, has been 
shown to ameliorate CKD-related complications [12-19]. 
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 Regarding renal anemia in CKD, IS accumulation inhibits the hypoxia-inducible 
factor and thus reduces EPO production [20]. Furthermore, IS removal improves the 
effect of ESA on anemia in late-stage CKD patients [21], indicating that IS mediates 
renal anemia via EPO regulation. However, it is not completely clear how IS 
accumulation impacts iron metabolism in CKD.  
    In the present study, we evaluated the effect of IS on iron metabolism, and found 
that IS augments hepatic hepcidin production, and in a mouse model of 
adenine-induced CKD, mice with a high IS concentration showed increased hepatic 
and plasma hepcidin levels, decreased ferroportin expression in the duodenum, and 
increased iron content in the spleen. These changes were ameliorated by AST-120 
treatment. Our findings suggest that IS accumulation leads to increases in hepcidin, 
which in turn dysregulates iron metabolism in CKD. 
 
Materials and Methods 
Chemicals and reagents 
Indoxyl sulfate potassium salt, adenine sulfate, and AST-120 (Kremezin™) 
were purchased from Sigma-Aldrich (St. Louis, MO, USA), Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan), and Kureha Corporation (Tokyo, Japan), respectively. 
N-acetyl cysteine (NAC), an antioxidant drug, and CH-223191, an inhibitor of AhR, 
were obtained from Sigma-Aldrich. The following commercially available antibodies 
were used for this study: anti-NRAMP2 (DMT1) antibody, anti-ferritin heavy chain 
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(FTH), anti-ferritin light chain (FTL), and anti-AhR antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA); anti-transferrin receptor 1 (TfR1) antibody 
(Zymed Technologies; Carlsbad, CA, USA); anti-FPN antibody (Alpha Diagnostics; 
San Antonio, TX, USA); anti-α-tubulin (San Diego, CA, USA), which was used as a 
protein loading control; and anti-Histone H3 antibody (Abcam, Cambridge, UK), 
which was used as a loading control in the case of nuclear proteins.  
 
Experimental animals and treatment 
All experimental procedures involving animals were performed in 
accordance with the guidelines of the Animal Research Committee of Tokushima 
University Graduate School (Permit Number: 13095). Eight-week-old male C57BL6/J 
mice were purchased from Nippon CLEA (Tokyo, Japan). The mice were maintained 
under conventional conditions, with a regular 12-hour light/dark cycle and free access 
to food (Type NMF; Oriental Yeast, Tokyo, Japan) and water during the study. Dietary 
adenine administration has been used to induce CKD in rodents [22]. [Animal 
experiment 1]: We used a new protocol involving intraperitoneal adenine 
administration, as previously described [23]; however, we modified the protocol of the 
previous study in that we administered 100 mg/kg of adenine three times per week for 
four weeks. One week after the start of adenine administration, serum creatinine was 
elevated by approximately twofold (vehicle vs. adenine: 0.50 ± 0.07 mg/dL vs. 0.87 ± 
0.15 mg/dL; p < 0.01); the mice that were receiving adenine were then divided into two 
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groups and treated for three more weeks; specifically, a “normal diet” group and an 
“AST-120” group, in which the normal diet was supplemented with 5% AST-120, 
were established [13, 19]. A control group received a normal diet, as well as 
intraperitoneal vehicle administration. [Animal experiment 2]: To test the direct IS 
effect on hepcidin, 0.1% IS (200 mg (800 µmol)/kg/day) was administered to the mice 
in their drinking water for two weeks as previously described [19]. The mice were 
euthanized by intraperitoneal over-dose injection of pentobarbital, their blood was 
collected, and their tissue was removed and stored at -80°C until use. 
 
Hematological analysis 
Whole blood cell counts were performed by Shikoku Chuken Co. Ltd. 
(Kagawa, Japan), and serum creatinine levels were determined using an alkaline picrate 
based assay (LabAssay Creatinine Kit, Wako Pure Chemical Industries Ltd., Osaka, 
Japan). 
 
Measurement of plasma iron levels, plasma ferritin levels, and tissue iron 
concentration 
Plasma iron levels and tissue iron concentrations were measured using an 
iron assay kit according to the manufacturer’s instructions (Metallo Assay; 
Metallogenics Co. Ltd.; Chiba, Japan), as previously described [24-26]. Plasma ferritin 
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levels were determined by a Mouse Ferritin ELISA Kit (Immunology Consultants 
Laboratory, Newberg, OR) according to the manufacturer’s instructions. 
 
Cell culture 
HepG2, a human hepatoma cell line, was purchased from the Japanese 
Collection of Research Bioresources (Osaka, Japan). The methods of cell culture have 
been previously described [26]. In some experiments, the cells were pre-treated for one 
hour with either 100 µM tempol (ROS scavenger), 10 µM BAY11-7082 (NF-κB 
inhibitor), 100 µM NAC (antioxidant drug), or 10 µM CH-223191 (AhR inhibitor) 
before stimulation with IS. In other experiments, HepG2 cells were cultured in bovine 
serum albumin (BSA) (40g/L) containing DMEM [11]. BSA was purchased from 
Wako Pure Chemical Industries, Ltd., and the concentration of endotoxin in BSA 
solution was 0.03 ng/mL as detected using a Limulus Amebocyte Lysate assay 
(Pierce™ LAL Chromogenic Endotoxin Quantitation Kit, Thermo Fisher Scientific Inc. 
Waltham, MA, USA). 
 
RNA extraction and evaluation of mRNA expression levels 
The RNA extraction, cDNA synthesis, and quantitative RT-PCR methods 
have been described previously [25]. The primer sets used were as follows: 5′
-ATGTCGCCTCCAGATACCAC-3′ and 5′-CCTCTCCCGTGTACAGCTTC-3′ 
for mouse erythropoietin (EPO), 5′-CTGCCTGTCTCCTGCTTCTC-3′ and 5′- 
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AGATGCAGATGGGGAAGTTG-3 ′  for mouse hepcidin-1, 5 ′
-CTCCGAACAATCACTGCTGA-3′ and 5′-CCTCCCCTGTGTSCSGCTTC-3′ 
for human hepcidin, 5 ′ -CTGCCTTTCCCACAAGATGT-3 ′  and 5 ′
-CAGTTATCCTGGCCTCCGTTT-3 ′  for human AhR, and 5 ′
-GCTCCAAGCAGATGCAGCA-3′  and 5′ -CCGGATGTGAGGCAGCAG-3′ 
for 36B4 as an internal control. The expression levels of all target genes were 
normalized using 36B4, and the values were compared to the control group in terms of 
relative fold changes. 
 
Protein extraction and western blot analysis 
Protein preparation was done and western blotting was performed as 
previously described [25]. Densitometry of the visualized bands was quantified using 
Image J 1.38x software. Protein staining by Ponceau S solution was used as a protein 
loading control in the duodenum. 
 
Measurement of intracellular reactive oxidative species levels 
Intracellular ROS were detected using dichlorofluorescin diacetate 
(DCFH-DA; Sigma-Aldrich). HepG2 cells were stimulated, for various time periods, 
using 250 µM IS; then, they were incubated with 10 µM DCFH-DA at 37°C for 30 
minutes. After washing, ROS production was quantified at 488 and 532 nm using a 
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microplate reader (FilterMax F3 Multi-Mode Microplate Reader; Molecular Devices 
LLC, Sunnyvale, CA, USA).  
 
Small interfering RNA experiments 
Small interfering RNA (siRNA) targeting human AhR and a non-targeting 
siRNA control sequence were commercially obtained from Sigma Aldrich (Mission 
siRNA; Tokyo, Japan). Transfection was performed as previously described [26]. 
Briefly, subconfluent HepG2 cells were transfected for 24 hours with 25 nM siRNA 
using the RNAiMAX® reagent and OPTI-MEM® (Life Technologies, Inc.). In all 
experiments, transfected HepG2 cells were used 48 hours after transfection. 
 
Measurement of IS and hepcidin concentrations in plasma and cell culture medium 
IS levels in mouse plasma were measured using high performance liquid 
chromatography. The concentrations of human and mouse hepcidin-25 were 
quantitatively analyzed as previously described [27]. In brief, surface-enhanced laser 
desorption ionization time of flight mass spectrometry (SELDI-TOF MS) was used to 
analyze hepcidin-25. The molecular sizes of peptides at 2789 m/z matched with the 
reported sizes of hepcidin-25, and the serum peptide at 2789 m/z was identified as 
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hepcidin-25 by collision-induced dissociation tandem MS. The assays were performed 
by Medical Care Proteomics Biotechnology Co. Ltd. (Kanazawa, Japan).  
 
Evaluation of iron-regulatory protein iron-responsive element binding activity  
The interaction between iron-regulatory protein (IRP) and iron-responsive 
element (IRE) was evaluated using an EMSA kit (LightShift Chemiluminescent RNA 
EMSA Kit; Thermo Fisher Scientific Inc., Rockford, IL, USA) as previously reported 
[24]. Semi-quantification for IRP-IRE binding activity was performed using ImageJ 
1.38X software. 
 
Statistical analysis 
Data are presented as means ± standard deviation (SD). An unpaired, 2-tailed, 
Student’s t-test was used for comparisons between the two groups. For comparisons 
between more than two groups, the statistical significance of each difference was 
evaluated using a post-hoc test (either Dunnett’s method or Tukey-Kramer’s method). 
P-values < 0.05 indicated statistical significance. 
 
Results 
Effect of IS on hepcidin expression in liver and cultured hepatic cell line 
12  
 IS stimulated hepcidin mRNA expression in a dose-dependent manner in 
HepG2 cells (Figure 1A). Similarly, hepcidin secreted from HepG2 cells was increased 
by IS stimulation (Figure 1B). AhR is a receptor for IS, and activated AhR is 
translocated from the cytosol to the nucleus, where it promotes the transcription of 
target genes [28]. Indeed, IS stimulation promoted nuclear translocation of AhR in 
HepG2 cells at 30 minutes or later in the present study (Figure 1C). Therefore, we used 
RNA interference to check whether AhR is involved in IS-induced hepcidin 
upregulation and observed that the siRNA reduced AhR mRNA levels to 27.0 ± 3.0% 
of the control (p < 0.01) and reduced AhR protein levels to 38.9 ± 16.7% of the control 
(p < 0.01). Silencing of AhR diminished IS-induced hepcidin expression (Figure 1D). 
Similarly, pharmacological AhR inhibition using CH-223191 suppressed IS-induced 
hepcidin expression (Figure 1E). These findings suggest that IS increases hepcidin 
expression via an AhR-mediated pathway. 
 
Influence of albumin on IS-induced hepcidin expression 
 Uremic toxins such as IS exist as protein-bound toxins in the blood. 
Therefore, we tested IS action on hepcidin in HepG2 cells cultured with BSA 
containing DMEM, and confirmed that IS augmented hepcidin mRNA expression 
similarly in HepG2 cells cultured with DMEM with BSA as in those cultured with 
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DMEM without BSA (Figure 1F). Moreover, there was no difference in basal hepcidin 
expression regardless of BSA inclusion.  
 
Involvement of oxidative stress in IS-induced hepcidin expression  
IS causes oxidative stress and the consequent activation of the NF-ĸB 
pathway in endothelial cells and proximal tubular cells [29-31]. Similar to previous 
findings, IS caused oxidative stress in HepG2 cells in the present study (Figure 2A), 
and the IS-induced oxidative stress was suppressed by tempol, a superoxide scavenger 
(Figure 2B). IS-induced hepcidin upregulation was also suppressed by NAC or 
BAY11-7082, an inhibitor of NF-ĸB (Figures 2C, D, and E). With regard to the 
relationship between oxidative stress and the AhR pathway, tempol failed to block 
IS-induced translocation of AhR to the nucleus from the cytosol (Figure 2F). 
Conversely, AhR knockdown did not prevent IS-mediated oxidative stress in HepG2 
cells (Figure 2G). Moreover, concomitant treatment with AhR siRNA and 
BAY-11-7082 almost blocked IS-induced hepcidin expression (Figure 2H). These 
results suggest that IS-induced hepcidin expression is also mediated via the oxidative 
stress-NF-ĸB pathway, and that it is independent of the AhR pathway. 
 
Changes in hepcidin levels in adenine-induced CKD mice 
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 To assess iron metabolism in CKD, we used mice with adenine-induced 
CKD. In adenine-induced CKD mice, hepatic hepcidin expression and plasma hepcidin 
concentration were significantly increased four weeks after the start of adenine 
administration (Figure 3A and B). These increases in both hepatic hepcidin expression 
and plasma hepcidin concentration were diminished by AST-120 treatment. As shown 
in Figure 3C, hepcidin concentration was positively correlated with IS levels, 
suggesting that IS is closely associated with hepcidin levels. These results indicate that 
IS accumulation involves hepcidin regulation in CKD mice. 
 
Alterations in tissue iron content in adenine-induced CKD mice  
We examined the impact of IS accumulation on the tissue iron content in 
adenine-induced CKD mice. As shown in Table 2, iron content was elevated in the 
spleen and skeletal muscle in adenine-induced CKD mice, and these increases in iron 
content were subsequently restored by AST-120 treatment. Duodenal iron content was 
also increased in adenine-induced CKD mice, but it was not changed by AST-120 
treatment. On the other hand, while CKD mice presented with decreased iron content 
in the liver and kidney, AST-120 did not ameliorate this effect. The findings of 
decreased plasma iron levels and increased plasma ferritin levels in the adenine-induced 
CKD mice are compatible with functional iron deficiency, and both in the iron and 
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ferritin levels in the blood were ameliorated by AST-120 treatment. These results 
indicate impaired iron distribution and utilization in CKD mice. 
 
Ferroportin expression in the duodenum and spleen 
As described above, hepcidin regulates cellular iron efflux via the 
internalization and degradation of FPN; hepcidin upregulation in CKD mice might 
therefore reduce the expression of FPN. As expected, FPN expression was diminished 
in the duodenum of CKD mice (Figure 4A), and its expression levels were restored by 
AST-120 treatment. In contrast, splenic FPN expression was augmented in CKD mice, 
and this change was also reversed by AST-120 (Figure 5A). In the spleens of CKD 
mice, FPN mRNA expression was increased and IRP-IRE binding activity was reduced, 
which was consistent with the increased FPN protein expression. The changes in FPN 
mRNA and IRP activity were also improved by AST-120 treatment, which 
corresponded with the reduction of FPN expression (Figure 5G and H). IRP-IRE 
binding activity was regulated by iron content, and the change in IRP activity 
corresponded with changes in splenic iron content. These findings suggest that FPN is 
post-transcriptionally regulated, independently of hepcidin, in the spleens of CKD 
mice. 
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The protein expression of iron importers and iron storage in the duodenum and spleen 
Next, we examined the protein expression of iron importers and iron storage 
in the duodenum and spleen. In the duodenum, the expression levels of DMT1, FTH, 
and FTL did not differ among the three groups (Figure 4B-D). Although no difference 
in DMT1 expression was seen, levels of TfR were decreased, and those of FTH and 
FTL were elevated in the spleens of CKD mice. These changes were all reversed by 
AST-120 treatment (Figure 5B-E). Moreover, splenic hepcidin expression was 
significantly reduced in adenine-induced CKD mice, which tended to be restored by 
AST-120 treatment (Figure 5F). 
 
Effect of IS removal on anemia in adenine-induced CKD mice 
Adenine-induced CKD mice demonstrated microcytic hypochromic anemia 
after four weeks of adenine treatment (Table 3). Treatment using AST-120 improved 
impaired iron absorption and utilization in adenine-induced CKD mice, and renal anemia 
was partly prevented by AST-120 treatment. CKD-induced elevation of plasma creatinine 
was slightly suppressed by AST-120 at four weeks (Table 1), and renal EPO expression 
remained at low levels in CKD mice, despite AST-120 treatment (Figure 6). In addition, 
there were no differences in plasma creatinine and the degree of anemia between the 
adenine-CKD mice and the adenine-CKD mice treated with AST-120 after two weeks of 
adenine treatment and one week of AST-120 treatment (Tables 1 and 3). These data 
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suggest that AST-120 restored iron incorporation and utilization by suppressing a 
pathway that is hepcidin/FPN-dependent and EPO-independent. 
 
Changes in mRNA expression of the inflammatory cytokines  
 IL-6 plays an important role in hepcidin regulation [32]. We examined the 
participation of inflammatory cytokines in hepcidin expression in adenine-CKD mice. As 
shown in Figure 7, the mRNA expression of IL-6, as well as IL-1ß and TNF-α, was 
increased in the kidneys of adenine-CKD mice. In contrast, the mRNA expression of 
those genes was decreased in the livers of adenine-CKD mice, indicating a lack of 
involvement of inflammatory cytokines in hepcidin regulation in the livers of 
adenine-CKD mice. 
 
Direct effect of IS on hepcidin in mice with IS treatment 
We examined whether IS has a direct effect on hepatic hepcidin expression 
using mice that had been administered IS. IS treatment augmented hepatic hepcidin 
mRNA expression as well as plasma hepcidin concentration (Figure 8A and B). IS 
administration also induced mild anemia despite no difference in plasma creatinine 
levels between the control mice and those that were administered IS (Figure 8C and 
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Table 4). Therefore, IS directly affects hepcidin regulation independent of renal 
function.  
 
 
Discussion  
In the in vitro experiments of the present study, IS augmented hepatic 
hepcidin expression via a pathway that depended on both AhR and oxidative stress. 
Similarly, hepatic and plasma hepcidin levels were increased in the in vivo experiments 
using adenine-induced CKD mice. The CKD mice also showed decreased FPN 
expression in the duodenum and increased splenic iron concentrations. The alterations 
in iron metabolism in the CKD mice were ameliorated by AST-120, which removes IS. 
These observations suggest, for the first time, the involvement of IS in iron metabolism 
in CKD.  
Hepcidin was first identified as an antimicrobial peptide and it plays an 
important role in the regulation of iron metabolism [3]. Specifically, hepcidin regulates 
cellular iron efflux via both the internalization and degradation of FPN [4]. Therefore, 
CKD-related increases in hepcidin levels contribute to the intracellular sequestration of 
iron, as well as impaired absorption of iron from the duodenum, and such changes 
promote functional iron deficiency in CKD. Indeed, several studies have shown that 
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the serum hepcidin concentration is elevated in CKD, which contributes to whole-body 
iron dysregulation. Moreover, elevated serum hepcidin levels are correlated with serum 
ferritin levels and inflammatory markers in patients with CKD [5]. Adenine-induced 
CKD animals show increases in hepatic hepcidin, as well as abnormal iron metabolism 
[6, 7]. In the present study, we found that hepatic hepcidin expression and plasma 
hepcidin concentration were elevated in adenine-induced CKD mice. These hepcidin 
increases were rectified by the removal of IS. The present study is the first to reveal the 
association between IS and hepcidin regulation.  
To investigate the mechanism by which IS regulates hepcidin concentrations, 
we used HepG2 cells and found that IS also increased hepcidin expression in these 
cells. Previously, Schroeder et al. demonstrated that IS is a ligand of AhR, and that IS 
acts via AhR [28]. In the current investigation, IS promoted the translocation of AhR to 
the nucleus from the cytosol in HepG2 cells, and the IS-induced hepcidin upregulation 
was reversed by AhR silencing. Similarly, previous studies have shown that various IS 
actions are prevented by AhR silencing [33]. Taken together, clearly the effect of IS on 
hepcidin is exerted through an AhR-mediated pathway.  
IS is known to cause oxidative stress; consequently, the toxin activates 
NF-κB signaling [29-31, 34]. In the present study, IS-induced hepcidin augmentation 
was suppressed by both a free radical scavenger and an NF-κB inhibitor, suggesting 
that the IS-induced oxidative stress-NF-κB axis is involved in hepcidin regulation. 
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However, IS-induced oxidative stress was not reduced by AhR siRNA, and tempol did 
not inhibit the IS-induced translocation of AhR to the nucleus. In addition, IS-induced 
hepcidin upregulation was almost completely abolished by the simultaneous inhibition 
of the AhR and NF-κB pathways. These results suggest that IS/oxidative stress-induced 
hepcidin expression occurs independently of any AhR-mediated pathway.  
In contrast to our results, several studies have shown that hepcidin is 
downregulated by oxidative stress induced by alcohol [35] or the hepatitis C virus [36]. 
However, pathophysiologically relevant H2O2 levels have been shown to upregulate 
hepcidin expression via STAT3 [37]. In terms of the effect of NF-κB on hepcidin, a 
previous study showed that LPS-induced hepcidin upregulation is mediated by NF-κB–
dependency, which is similar to our finding [38]. In contrast, ceramide-induced 
hepcidin regulation is not involved in the NF-κB pathway [39]. Therefore, oxidative 
stress and NF-κB have dual characteristics as either positive or negative regulators of 
hepcidin. 
Uremic solutes normally exist as protein-bound toxins, and several studies, 
including the present study, used high concentrations of IS relative to the 
concentrations in uremic CKD patients in the in vitro experiments [11, 40]. Therefore, 
we tested the IS effect on hepcidin in HepG2 cells by using both the free concentration 
(25µM) in albumin-free DMEM and the protein-bound maximum concentration (250 
µM) in DMEM containing BSA. Twenty-five µM of IS induced an approximately 
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twofold increase in hepcidin mRNA expression in HepG2 cultured with BSA-free 
DMEM, and 250 µM IS also increased hepcidin mRNA expression in HepG2 cultured 
with BSA-containing DMEM. In addition, there was no difference in basal hepcidin 
mRNA expression in DMEM regardless of BSA inclusion, indicating no impact of 
albumin on hepcidin expression (Figure 1F). Thus, hepcidin expression was 
upregulated by IS at the free concentration and protein-bound concentration doses in 
HepG2 cells under our experimental condition. 
Inflammatory cytokines (i.e., IL-6) are also important factors in hepcidin 
regulation [32]. As expected, the expression of IL-6, IL-1ß, and TNF-α mRNA was 
upregulated in the kidney in CKD mice. However, it was decreased in the liver. 
Although the reason for the discrepancy in inflammatory cytokine expression between 
the kidney and liver remains unclear, inflammatory cytokines might not be associated 
with the regulation of hepatic hepcidin in an adenine-induced CKD mouse model. 
 Regarding alterations in iron distribution in CKD mice, iron concentrations 
in the spleen, duodenum, and skeletal muscle were increased. Plasma ferritin was also 
increased, though plasma iron was decreased, indicating that iron absorption and 
utilization were impaired. These alterations were mostly ameliorated by AST-120 
treatment. It follows that IS removal, and the resulting inhibition of hepcidin, might 
improve (1) iron metabolism and (2) iron utilization in CKD. Consistent with this 
result, decreased expression of FPN in the duodenum was restored by AST-120 
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treatment in CKD mice, indicating that IS removal affects hepcidin levels. Conversely, 
CKD mice showed increased FPN expression in the spleen, which was reduced by 
AST-120 treatment. It is not clear why the discrepancy of increased FPN expression in 
the spleen combined with elevated hepcidin in the liver and serum is present in CKD 
mice. FPN expression is controlled by both transcriptional and post-transcriptional 
regulation, as well as by the translational regulation of hepcidin-dependent internalization. 
In macrophages, FPN transcription is induced by iron, as well as by heme protein [41]. 
Additionally, FPN mRNA has an iron-responsive element in the 5′-region [42], and its 
translation is therefore increased by high iron levels because it can bind to iron 
regulatory protein 1 [43]. In the spleens of CKD mice, FPN mRNA was increased and 
IRP activity was reduced, which is consistent with the understanding that increased 
FPN protein expression is responsible for the transcriptional upregulation. Therefore, 
we suggest that the increased FPN expression seen in CKD mice is likely responsible 
for the accumulation of iron in the spleen, and that this accumulation overwhelms 
hepcidin-mediated mechanisms. In addition, hepcidin expression has been observed in 
not only the liver, but also the heart [44], kidney [45], brain [46], and spleen [47]. 
Although the function of extra-hepatic hepcidin remains unknown, it might influence 
local iron regulation. In the present study, hepcidin expression was reduced in the 
spleens of adenine-CKD mice, indicating the involvement of local hepcidin on the 
regulation of splenic FPN expression. Further examination is necessary to clarify 
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whether there is a coordinated regulation of (1) peripheral FPN expression or (2) 
hepatic hepcidin levels.  
 CKD mice showed renal anemia compatible with iron-deficient anemia, 
which is caused by iron sequestration and impaired iron utilization, as well as by 
reduced renal EPO production. The renal anemia was slightly improved by AST-120 
treatment, perhaps because consequent reductions in hepcidin restored iron utilization. 
In previous studies, hepcidin inhibition ameliorated erythropoiesis in (1) a model of 
CKD combined with renal anemia, (2) hepcidin-deficient mice, and (3) mice that had 
been treated with a hepcidin inhibitor [7, 48]. This suggests that hepcidin inhibition 
mobilizes iron and improves iron utilization. In the same way, the removal of IS using 
AST-120 ameliorated iron accumulation in the spleen and skeletal muscle, as well as 
elevated plasma ferritin levels. Conversely, the treatment reduced plasma iron levels in 
CKD mice, indicating that iron mobilization in tissues with ectopic iron accumulation 
had been improved. Moreover, AST-120 slowed the progression of renal dysfunction, 
as estimated by plasma creatinine level; however, the decrease of renal EPO expression 
in CKD mice was not changed by IS removal. Therefore, IS removal ameliorates renal 
anemia via the restoration of iron utilization rather than through increased EPO 
production. Additionally, cyanate, formed spontaneously from accumulated urea, 
decreases EPO activity in order to induce EPO carbamylation [49, 50], which might 
promote inadequate erythropoiesis in CKD.  
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A recent clinical study (Evaluating Prevention of Progression in CKD 
[EPPIC] trials) demonstrated that AST-120 fails to prevent disease progression in 
patients with moderate to severe CKD [51]. Moreover, a subgroup analysis within the 
EPPIC study revealed that AST-120 delays the primary end point (dialysis initiation, 
kidney transplantation, or serum creatinine doubling) in American patients [52]. Thus, 
it remains controversial whether IS removal prevents renal dysfunction in CKD. 
Nonetheless, the uremic toxicity of IS accumulation causes dysfunction in various 
organs through multiple pathways. Further examination is necessary to elucidate the 
effect of AST-120 on renal anemia in CKD. 
 In conclusion, IS induces hepcidin production via a pathway that involves 
both AhR and oxidative stress; this results in iron sequestration and impaired iron 
utilization in CKD. AST-120 ameliorates iron metabolism by inhibiting hepcidin 
increases, promoting iron mobilization, and ameliorating erythropoiesis. These findings 
suggest that a therapeutic strategy of uremic toxin removal may be useful for correcting 
impaired iron metabolism in CKD. 
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Table 1. Characteristics of the control mice and adenine-CKD mice with or without AST-120 treatment 
Data are presented as means ± SD; n = 4-15, respectively. *P < 0.05, **P < 0.01 vs. control mice at the same week. #P < 0.05, ##P < 0.01 vs. adenine diet at the same week. 
IS; indoxyl sulfate. 
  
 
1W  2W  4W 
  Control Adenine  Control Adenine Adenine+AST120  Control Adenine Adenine +AST120 
Body weight (g)  24.7 ± 2.2 22.5 ± 0.7  26.8 ± 1.1 20.8 ± 1.8** 20.4 ± 0.6**  28.2 ± 2.0 18.2 ± 1.5** 18.5 ± 1.3** 
Right kidney weight (mg) 131.5 ± 12.5 163.8 ± 14.4*  143.0 ± 10.4 179.3 ± 17.6* 148.5 ± 14.1#  156.9 ± 10.5 152.1 ± 13.3 158.9 ± 12.2 
Left kidney weight (mg) 122.3 ± 13.2 156.3 ± 14.2**  143.8 ± 13.4 170.3 ± 7.5 149 ± 15.2  149.7 ± 10.9 148.7 ± 17.5 153.9 ± 17.5 
Plasma creatinine (mg/dL) 0.50 ± 0.07 0.87 ± 0.15**  0.31 ± 0.07 1.08 ± 0.21** 0.97 ± 0.03**  0.36 ± 0.11 1.67 ± 0.38** 1.33 ± 0.33**# 
Table 2. Tissue iron content, plasma iron levels, and plasma ferritin concentration 
   Control Adenine Adenine + AST-120 
Spleen (µg/g tissue weight) 6.1 ± 1.1 19.0 ± 7.5* 8.4 ± 0.9# 
Liver (µg/g tissue weight) 19.9 ± 3.8 9.3 ± 1.3** 9.8 ± 1.3** 
Duodenum (µg/g tissue weight) 8.0 ± 3.9 14.3 ± 6.9* 11.5 ± 5.7 
Kidney (µg/g tissue weight) 7.6 ± 3.7 1.4 ± 0.7** 2.4 ± 1.5* 
Gastrocnemius muscle (µg/g tissue weight) 3.6 ± 2.7 7.7 ± 5.4** 3.1 ± 0.6# 
Plasma iron (µg/dL) 108.5 ± 16.8 78.6 ± 22.9* 111.7 ± 36.6# 
Plasma ferritin (ng/mL) 504 ± 146 2842 ± 726**  1882 ± 571**## 
Data are presented as means ± SD; n = 3-14, respectively. *P < 0.05, **P < 0.01 vs. control mice. #P < 0.05, ##P < 0.01 vs. adenine diet.  
  
Table 3. Hematological data of the control mice and adenine-CKD mice with or without AST-120 treatment 
Data are presented as means ± SD; n = 3-15, respectively. *P < 0.05, **P < 0.01 vs. control mice at the same week. #P < 0.05, ##P < 0.01 vs. adenine diet at the same week. 
RBC; red blood cell, Hb; hemoglobin, Ht; hematocrit, MCV; mean corpuscular volume, MCH; mean corpuscular hemoglobin, MCHC; mean corpuscular hemoglobin 
concentration, WBC; white blood cell, Plt; platelet. 
 
  1W  2W  4W 
  Control Adenine  Control Adenine Adenine+AST120  Control Adenine Adenine+AST120 
RBC (× 104/µL) 914 ± 79 726 ± 68*  857 ± 26 688 ± 93* 720 ± 40*  901 ± 63 643 ± 57** 718 ± 99**# 
Hb (g/dL) 14.2 ± 1.2 11.4 ± 1.0*  13.7 ± 0.3 10.1 ± 1.4** 10.6 ± 0.7*  13.7 ± 0.9 8.8 ± 0.7** 10.1 ± 1.5**# 
Ht (%) 43.4 ± 3.5 32.4 ± 3.1*  39.6 ± 0.9 29.7 ± 4.5** 31.4 ± 1.7**  40.7 ± 3.1 26.8 ± 2.5** 31.4 ± 7.0**# 
MCV (fL) 47.7 ± 0.6 44.5 ± 0.5**  46.3 ± 0.5 43.0 ± 1.3** 43.7 ± 0.5**  45.3 ± 0.8 41.7 ± 1.0** 43.4 ± 3.3 
MCH (pg) 15.5 ± 0.1 15.7 ± 0.6  15.9 ± 0.2 14.7 ± 0.2** 14.8 ± 0.2**  15.2 ± 0.4 14.0 ± 0.3** 14.0 ± 0.3** 
MCHC (g/dL) 32.7 ± 0.4 35.2 ± 1.2**  34.5 ± 0.1 34.2 ± 1.0 33.9 ± 0.4  33.8 ± 1.3 33.5 ± 1.1 32.5 ± 2.3 
WBC (/µL) 5200 ± 2100 3700 ± 700  3700 ± 1300 4300 ± 1800 4600 ± 2600  5200 ± 3200 2600 ± 1100** 2900 ± 1200* 
Plt (× 104/µL) 51.8 ± 5.2 68.0 ± 12.6*  51.0 ± 12.2 66.3 ± 17.9 63.6 ± 17.6  45.2 ± 16.2 79.3 ± 15.3** 94.6 ± 18.7** 
Table 4. Characteristics and hematological data of mice with vehicle- or IS-treatment for two 
weeks  
 Vehicle IS 
Body weight (g)  27.6 ± 2.4 27.8 ± 0.3 
Right kidney weight (mg) 155.3 ± 11.0 163.8 ± 22.5 
Left kidney weight (mg) 152.0 ± 9.9 159.5 ± 8.9 
Plasma creatinine (mg / dL) 0.37 ± 0.14 0.42 ± 0.22 
RBC (× 104/µL) 955 ± 53 721 ± 62** 
Hb (g/dL) 14.5 ± 0.9 11.3 ± 0.9** 
Ht (%) 44.7 ± 2.9 33.4 ± 3.1** 
MCV (fL) 46.5 ± 0.6 46.3 ± 0.5 
MCH (pg) 15.2 ± 0.1 15.7 ± 0.4 
MCHC (g/dL) 32.5 ± 0.5 33.9 ± 1.2 
WBC (/µL) 4300 ± 900 5600 ± 1400 
Plt (× 104/µL) 39.7 ± 7.0 50.7 ± 6.9 
Data are presented as means ± SD; n = 4, respectively. *P < 0.05, **P < 0.01 vs. vehicle mice. 
Figure legends 
Figure 1. Effect of indoxyl sulfate (IS) on hepcidin expression in liver and HepG2 cells. 
(A) IS induces hepcidin mRNA expression in HepG2 cells in a dose-dependent manner. 
Values are expressed as means ± SD. *P < 0.05, **P < 0.01 (vs. vehicle treatment); n = 
6-8 in each group. (B) Hepcidin concentration secreted from HepG2 cell to culture 
media. Values are expressed as means ± SD. *P < 0.05 (vs. vehicle treatment); n = 4 in 
each group. (C) IS translocates aryl hydrocarbon receptor (AhR) to the nucleus from the 
cytoplasm in HepG2 cells. Left panel: representative protein expression levels of AhR 
and tubulin, and semi-quantitative densitometry analysis of AhR expression in the 
cytoplasm. Right panels: representative protein expression of AhR and Histone-H3, and 
semi-quantitative densitometry analysis of AhR expression in the nucleus. Values are 
expressed as means ± SD. *P < 0.05, **P < 0.01 (vs. time at 0 min); n = 5 in each group. 
(D) Treatment with AhR siRNA inhibits IS-induced hepcidin upregulation in HepG2 
cells. Forty-eight hours after siRNA transfection, cells were treated with either IS or 
vehicle. Values are expressed as means ± SD. *P < 0.05, **P < 0.01; n = 14 in each 
group. (E) Treatment with CH-223191 inhibits IS-induced hepcidin upregulation in 
HepG2 cells. Cells were treated with either IS or vehicle 1 hour after CH-223191 
pretreatment. Values are expressed as means ± SD. **P < 0.01; n = 3 in each group. (F) 
High concentration of IS action on hepcidin mRNA in HepG2 cells cultured with or 
without BSA-containing DMEM. Values are expressed as means ± SD. *P < 0.05, **P 
< 0.01; n = 7 in each group. 
Figure 2. Effect of IS-induced oxidative stress on hepcidin expression in HepG2 cells. 
(A) Time course of IS-induced oxidative stress, as detected using 2′ ,7′
-dichlorofluorescin diacetate fluorescence. IS induces oxidative stress at 15 minutes or 
later. Values are expressed as means ± SD. *P < 0.05, **P < 0.01 (vs. time at 0 min); n 
= 7–8 in each group. (B) Pre-treatment with tempol inhibits IS-induced oxidative stress 
in HepG2 cells. Cells were treated with either IS or vehicle for 24 hours after 
pre-treatment with either vehicle or tempol. Values are expressed as means ± SD. *P < 
0.05, **P < 0.01; n = 8 in each group. (C) The effect of tempol, a superoxide scavenger, 
(D) N-acetyl cysteine, an-anti-oxidant agent, or (E) BAY-11-7082, an NF-κB inhibitor, 
on IS-induced oxidative stress in HepG2 cells. Values are expressed as means ± SD. *P 
< 0.05, **P < 0.01; n = 4-9 in each group. (F) Tempol has no inhibitory effect on 
IS-induced AhR translocation to the nucleus from the cytosol. Values are expressed as 
means ± SD. *P < 0.05, **P < 0.01; n = 8 in each group. (G) Effect of AhR silencing on 
IS-induced oxidative stress. Values are expressed as means ± SD. **P < 0.01; n = 11–
16 in each group. (H) The concomitant effect of AhR siRNA transfection and NF-κB 
inhibitor administration on IS-induced hepcidin expression in HepG2 cells. Values are 
expressed as means ± SD. **P < 0.01; n = 4 in each group. 
Figure 3. Changes in hepcidin levels in adenine-induced CKD mice with or without 
AST-120 treatment. (A) Hepcidin mRNA expression. Values are expressed as means ± 
SD. *P < 0.05, **P < 0.01, n = 4–11 in each group. (B) Plasma hepcidin concentration. 
Values are expressed as means ± SD. **P < 0.01; n = 4–8 in each group. (C) Plasma 
indoxyl sulfate concentration. Values are expressed as means ± SD. *P < 0.05, **P < 
0.01; n = 4–8 in each group. (D) Positive correlation between plasma hepcidin and IS 
concentration. 
Figure 4. Changes in the expression of duodenal iron metabolism-related proteins in 
mice. Upper panel: Representative immunoblots for (A) FPN, (B) DMT1, (C) FTH, (D) 
FTL and protein staining. Lower panel: Semi-quantitative densitometric analyses of 
DMT1, FPN, FTH, and FTL protein levels normalized to protein staining. Values are 
expressed as means ± SD. **P < 0.01; n = 11–15 in each group. 
Figure 5. Alterations in iron metabolism-related proteins in the spleen of mice. Upper 
panel: Representative immunoblots for (A) FPN, (B) DMT1, (C) TfR, (D) FTH, (E) 
FTL and tubulin. Lower panel: Semi-quantitative densitometric analyses of FPN, 
DMT1, TfR, FTH, and FTL protein levels normalized to tubulin. Values are expressed 
as means ± SD. **P < 0.01; n = 14–18 in each group. The mRNA expression of (F) 
hepcidin and (G) FPN in the spleen of mice. Values are expressed as means ± SD. *P < 
0.05, **P < 0.01; n = 7–12 in each group. (H) Upper panel: Representative IRP–IRE- 
binding bands. Lower panel: Semi-quantitative densitometry analysis of IRP activity in 
the spleen. *P < 0.05, **P < 0.01; n = 5 in each group. 
Figure 6. Erythropoietin mRNA expression in the kidney. Values are expressed as 
means ± SD. **P < 0.01; n = 10–11 in each group.  
Figure 7. IL-6, IL-1ß, and TNF-α mRNA expression in the kidney and liver of control 
mice and adenine-CKD mice. Values are expressed as means ± SD. *P < 0.05, **P < 
0.01; n = 3-7 in each group. 
Figure 8. (A) Hepcidin mRNA expression in the liver of vehicle-treated or IS-treated 
mice at 2 weeks. Values are expressed as means ± SD. **P < 0.01 (vs. vehicle 
treatment); n = 3–4 in each group. (B) Plasma hepcidin concentration. Values are 
expressed as means ± SD. *P < 0.05 (vs. vehicle treatment); n = 7–11 in each group. (C) 
Plasma indoxyl sulfate concentration. Values are expressed as means ± SD. **P < 0.05 
(vs. vehicle treatment); n = 4–8 in each group. 
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